A Real-World, multicentre, retrospective study of fast-acting insulin aspart in adult people with type 1 diabetes (PWD1) who were using intermittent or real-time continuous glucose monitoring (iCGM or rtCGM) in Belgium
Latest Information Update: 09 Aug 2021
At a glance
- Drugs Insulin aspart (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- 09 Aug 2021 New trial record
- 29 Jun 2021 Primary endpoint (The evolution of time in range (TIR, 70-180 mg/dl) at 6 (n=416) and 12 months (n=380).) has been met, as per results presented at the 81st Annual Scientific Sessions of the American Diabetes Association.
- 29 Jun 2021 Results presented at the 81st Annual Scientific Sessions of the American Diabetes Association.